{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:26:33Z","timestamp":1770524793983,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.rmr.2010.06.011","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T10:34:34Z","timestamp":1280831674000},"page":"685-692","source":"Crossref","is-referenced-by-count":20,"title":["Infliximab et sarco\u00efdose chronique. L\u2019exp\u00e9rience fran\u00e7aise \u00e0 propos de 31\u00a0cas"],"prefix":"10.1016","volume":"27","author":[{"given":"F.","family":"Jounieaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chapelon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Valeyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Israel Biet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wallaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2010.06.011_bib1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","article-title":"Sarcoidosis","volume":"361","author":"Baughman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2010.06.011_bib2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"American Thoracic Society","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib4","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.rmr.2010.06.011_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1345\/aph.1C249","article-title":"Infliximab treatment of sarcoidosis","volume":"37","author":"Serio","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rmr.2010.06.011_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jcp.47.5.423","article-title":"Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation","volume":"47","author":"Myatt","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.rmr.2010.06.011_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0091-6749(93)90352-G","article-title":"Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6\u00a0by alveolar macrophages from patients with sarcoidosis","volume":"91","author":"Steffen","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2010.06.011_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.127.1.251","article-title":"Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis","volume":"127","author":"Dai","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2010.06.011_bib9","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","article-title":"Refractory sarcoidosis responding to infliximab","volume":"124","author":"Roberts","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2010.06.011_bib10","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2010.06.011_bib11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/art.21468","article-title":"Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis","volume":"53","author":"Sweiss","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rmr.2010.06.011_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy","volume":"135","author":"Yee","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib13","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.rmed.2006.02.017","article-title":"Effectiveness of infliximab in treating selected patients with sarcoidosis","volume":"100","author":"Saleh","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib14","first-page":"484","article-title":"Treatment of severe sarcoidosis using TNF-alpha-inhibitor (infliximab)","volume":"168","author":"Milman","year":"2006","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.rmr.2010.06.011_bib15","first-page":"2446","article-title":"Successful treatment with infliximab of a patient with refractory sarcoidosis","volume":"148","author":"Fouchier","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.rmr.2010.06.011_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","article-title":"Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients","volume":"63","author":"Pritchard","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rmr.2010.06.011_bib17","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1002\/art.11357","article-title":"Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis","volume":"48","author":"Ulbricht","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rmr.2010.06.011_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-137-4-200208200-00022","article-title":"Infliximab therapy for complicated sarcoidosis","volume":"137","author":"O\u2019Connor","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-137-4-200208200-00021","article-title":"Infliximab therapy for complicated sarcoidosis","volume":"137","author":"Cook","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib20","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2010.06.011_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Sarcoidosis Investigators Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10227-005-0110-7","article-title":"Off-label dermatologic uses of anti-TNF-a therapies","volume":"9","author":"Alexis","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.rmr.2010.06.011_bib23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archderm.141.7.910","article-title":"Recalcitrant cutaneous sarcoidosis responding to infliximab","volume":"141","author":"Heffernan","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2133.2004.05769.x","article-title":"Infliximab therapy for sarcoidosis (lupus pernio)","volume":"150","author":"Haley","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1067\/mjd.2003.228","article-title":"Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy","volume":"48","author":"Mallbris","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib26","unstructured":"Baughman RP, Lower EE, Judson MA, Teirstein A, Schlenker-Herceg R, Barnathan E. Lupus pernio in sarcoidosis: clinical features and a target for therapy. Presented at the American Thoracic Society International Conference; May 20\u201325, 2005; San Diego, CA."},{"key":"10.1016\/j.rmr.2010.06.011_bib27","first-page":"413","article-title":"The use of infliximab in cutaneous sarcoidosis","volume":"2","author":"Meyerle","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2005.07.010","article-title":"Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease","volume":"118","author":"Candon","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.rmr.2010.06.011_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2007.03.003","article-title":"Biological and clinical effects of anti-TNFalpha treatment","volume":"7","author":"Valesini","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rmr.2010.06.011_bib31","first-page":"841","article-title":"Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib32","first-page":"469","article-title":"Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions","volume":"23","author":"Edrees","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rmr.2010.06.011_bib34","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2010.06.011_bib35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Centocor T48\u00a0Sarcoidosis Investigators","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2010.06.011_bib36","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2010.06.011_bib37","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/ard.2007.074104","article-title":"A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis","volume":"67","author":"Miceli-Richard","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rmr.2010.06.011_bib38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2249.2007.03428.x","article-title":"Linkage between Toll-like receptor (TLR) 2\u00a0promotor and intron polymorphisms: functional effects and relevance to sarcoidosis","volume":"149","author":"Veltkamp","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.rmr.2010.06.011_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2249.2007.03564.x","article-title":"Association of TNF polymorphisms with sarcoidosis, its prognosis and tumor necrosis factor(TNF)-alpha levels in Asian Indians","volume":"151","author":"Sharma","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.rmr.2010.06.011_bib40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MCP.0b013e3283043de7","article-title":"Genetics of sarcoidosis","volume":"14","author":"Grunewald","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s10038-007-0185-7","article-title":"Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis","volume":"52","author":"Medica","year":"2007","journal-title":"J Hum Genet"},{"key":"10.1016\/j.rmr.2010.06.011_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.lpm.2008.11.008","article-title":"Complications infectieuses de la sarco\u00efdose","volume":"38","author":"Dhote","year":"2009","journal-title":"Presse Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2010.06.011_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rmr.2010.06.011_bib45","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1469-0691.2006.01546.x","article-title":"Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections","volume":"12","author":"Moiton","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2010.06.011_bib46","first-page":"429","article-title":"Recommendations for the prevention and management of tuberculosis in patients taking infliximab","volume":"153","author":"Salmon-Ceron","year":"2002","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.rmr.2010.06.011_bib47","first-page":"471","article-title":"Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases","volume":"26","author":"Toussirot","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib48","first-page":"99","article-title":"Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab","volume":"25","author":"Almod\u00f3var","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rmr.2010.06.011_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","article-title":"Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \u201cClass Effect\u201d paradoxical phenomenon. Two case reports and litterature review","volume":"39","author":"Massara","year":"2010","journal-title":"Semin Arthritis Rheum"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S076184251000313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S076184251000313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T02:54:44Z","timestamp":1544324084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S076184251000313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S076184251000313X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2010.06.011","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}